



To NASDAQ OMX Copenhagen A/S
Announcement No. 26-09 / Copenhagen, 23 June 2009

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

Report pursuant to the Danish Securities Trading Act, Section 28a

Copenhagen – 23 June, 2009 – Pursuant to the Danish Securities Trading Act, Section 28a TopoTarget A/S (OMX: TOPO) is obliged to report on transactions by members of its board of directors, senior management and their related parties in shares issued by TopoTarget A/S and related securities.

| | |
|---------------------|---|
| Name | Håkan Åström |
| Reason | chairman of TopoTarget A/S |
| Issuer | TopoTarget A/S |
| ISIN codes | ISIN code for subscription rights: DK0060183515 |
| Transaction | Purchase of subscription rights |
| Trade date | 22 June 2009 |
| Market | NASDAQ OMX Copenhagen A/S |
| Number | 150,000 subscription rights purchased |
| Market value in DKK | 43,050 (150,000 subscription rights x 0,2870 DKK) |

TopoTarget A/S

For further information, please contact:

| | | |
|-------------------|-----------|-----------------|
| Peter Buhl Jensen | Telephone | +45 39 17 94 99 |
| CEO | Mobile | +45 21 60 89 22 |

Background information

About TopoTarget

TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. The company was founded and is run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. TopoTarget has a broad clinical pipeline but is currently focusing on the development of belinostat, which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours where it can be used in combination with full doses of chemotherapy, and is in phase III in PTCL. TopoTarget's expertise in translational research is utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget is directing its efforts on key cancer targets including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors. The company's first marketed product Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is

marketed by TopoTarget's own sales force in Europe and the US. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.